News UK biotechs T-Therapeutics and Alethio score big financings Two up-and-coming UK biotechs – T-Therapeutics and Alethio Therapeutics – have raised $133m and $90m, respectively, in impressive financing rounds.
News Novartis abandons Fabhalta trial in lupus nephritis A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.
News Females with autoimmune disease 'less likely to be believed' Women and girls with autoimmune diseases are more likely to have their condition misdiagnosed as psychiatric or psychosomatic than males, study finds.
News Novartis taps China's Abogen for autoimmunity TCE Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
News Amgen's Horizon buyout delivers Sjögren's disease win Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.
News Novartis halts CAR-T trials after patient deaths Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.